- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07576348
Electroacupuncture for Insomnia in Patients With Chronic Sciatica Due to Lumbar Disc Herniation: a Randomized Controlled Trial
4 mei 2026 bijgewerkt door: Shanghai Yueyang Integrated Medicine Hospital
The goal of this clinical trial is to learn if electroacupuncture can improve sleep in people with chronic sciatica caused by lumbar disc herniation.
It will also assess the safety of this treatment.
The main questions it aims to answer are whether electroacupuncture improves sleep quality and whether it reduces pain and improves daily function.
Researchers will compare electroacupuncture to a sham treatment, which looks like real acupuncture but has little or no therapeutic effect, to determine its effectiveness.
Participants will be randomly assigned to receive electroacupuncture or sham treatment, will receive treatment three times per week for four weeks, and will complete questionnaires about their sleep, pain, and daily activities.
Studie Overzicht
Toestand
Nog niet aan het werven
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Geschat)
114
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Ke Wang
- Telefoonnummer: +86 21-65161782-3136
- E-mail: wangke8430@163.com
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
Participants will be eligible if they meet all of the following criteria:
- Aged 18-75 years, of either sex;
- Diagnosis with lumbar disc herniation accompanied by unilateral chronic sciatica (disease duration ≥ 3 months);
- Experiencing moderate to severe radiating leg pain (below the knee), defined as a Numerical Rating Scale (NRS) score ≥ 4 at screening within the past 24 h;
- Diagnosis of chronic insomnia, with a Pittsburgh Sleep Quality Index (PSQI) total score > 7;
- Onset or exacerbation of insomnia temporally associated with the onset or worsening of sciatica symptoms;
- Willing to participate and able to provide written informed consent.
Exclusion Criteria:
Participants will be excluded if any of the following criteria are met:
- Spinal or structural conditions: lumbar spinal stenosis, spondylolisthesis, vertebral fracture, spinal infection (e.g., tuberculosis), or tumor;
- Surgical indications: cauda equina syndrome, conus medullaris syndrome, or other conditions requiring urgent surgical intervention;
- Severe systemic diseases: unstable cardiovascular, hepatic, renal, respiratory, or hematological disorders, or metabolic conditions that may significantly affect study outcomes (e.g., uncontrolled diabetes or thyroid disease);
- Neurological or psychiatric disorders: major neurological diseases (e.g., epilepsy, Parkinson's disease, dementia, multiple sclerosis) or severe psychiatric disorders (e.g., schizophrenia);
- Clinically significant depression or anxiety, defined as Patient Health Questionnaire-9 (PHQ-9) ≥ 10 and/or Generalized Anxiety Disorder-7 (GAD-7) ≥ 10;
- Other primary sleep disorders, including obstructive sleep apnea, narcolepsy, or restless legs syndrome;
- Use of centrally acting medications: regular use (≥ 3 days/week within 4 weeks prior to enrolment) of medications affecting the central nervous system (e.g., opioids, sedative-hypnotics, antidepressants) without an adequate washout period (≥ 2 weeks or longer depending on drug half-life);
- Irregular sleep patterns, including night shift work (≥ 2 times/week between 22:00-06:00) or highly irregular sleep-wake cycles;
- Pregnancy or lactation;
- History of substance abuse or dependence;
- Lumbar spine surgery or interventional procedures within the past 3 months;
- History of acupuncture treatment;
- Implanted electronic devices (e.g., pacemakers) or metal implants at acupuncture sites;
- Participation in another clinical trial within the past 3 months;
- Severe sensory or cognitive impairment affecting assessment compliance;
- Any other condition deemed by investigators to compromise safety or data integrity.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Electroacupunctuur
|
Electroacupuncture will be administered by a licensed acupuncturist.
Adhesive foam pads will be applied at each acupoint to enhance blinding.
Sterile needles will be inserted through the pads into the skin at predefined acupoints, including Sishencong (EX-HN1), bilateral Shenmen (HT7) and Sanyinjiao (SP6), Jiaji (EX-B2) at the L3-L5 levels (bilateral points at each segment), Shenshu (BL23), Dachangshu (BL25), and selected lower limb acupoints.
Electrical stimulation will be applied using a sparse-dense wave (2/10 Hz) for 30 minutes per session.
Treatment will be delivered three times per week for four weeks.
|
|
Sham-vergelijker: Schijnelektro-acupunctuur
|
Sham electroacupuncture will be administered by a licensed acupuncturist.
Adhesive foam pads will be applied at each non-acupoint to maintain blinding.
Sterile needles will be inserted superficially (2-3 mm) through the pads without manipulation or eliciting deqi sensation.
Electrical stimulation will be minimally applied only briefly at the beginning and end of each session to mimic the procedure.
Treatment duration and frequency will be identical to the electroacupuncture group (30 minutes per session, three times per week for four weeks).
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pittsburgh Sleep Quality Index (PSQI) total score
Tijdsspanne: Week 4
|
The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported instrument designed to assess sleep quality over the preceding month, with total scores ranging from 0 to 21, where higher scores denote poorer sleep quality.
|
Week 4
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Numerical Rating Scale (NRS) score for leg pain intensity
Tijdsspanne: Baseline, Week 2, Week 4, and Week 8
|
The 11-point Numerical Rating Scale (NRS) is a self-reported instrument used to assess average radiating leg pain intensity over the preceding 24 hours, with scores ranging from 0 to 10, where higher scores denote more severe pain.
|
Baseline, Week 2, Week 4, and Week 8
|
|
Numerical Rating Scale (NRS) score for low back pain intensity
Tijdsspanne: Baseline, Week 4, and Week 8
|
The 11-point Numerical Rating Scale (NRS) is a self-reported instrument used to assess average low back pain intensity over the preceding 24 hours, with scores ranging from 0 to 10, where higher scores denote more severe pain.
|
Baseline, Week 4, and Week 8
|
|
Oswestry Disability Index (ODI) score
Tijdsspanne: Baseline, Week 4, and Week 8
|
The Oswestry Disability Index (ODI) is a self-reported questionnaire used to assess disability related to lumbar spine disorders, with percentage scores ranging from 0% to 100%, where higher scores denote greater disability.
|
Baseline, Week 4, and Week 8
|
|
Insomnia Severity Index (ISI) score
Tijdsspanne: Baseline, Week 2, Week 4, and Week 8
|
The Insomnia Severity Index (ISI) is a self-reported instrument used to assess the subjective severity of insomnia, its impact on daytime functioning, and associated distress over the preceding two weeks, with total scores ranging from 0 to 28, where higher scores denote more severe insomnia.
|
Baseline, Week 2, Week 4, and Week 8
|
|
Pittsburgh Sleep Quality Index (PSQI) total score
Tijdsspanne: Week 8
|
The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported instrument designed to assess sleep quality over the preceding month, with total scores ranging from 0 to 21, where higher scores denote poorer sleep quality.
|
Week 8
|
|
Proportion of participants achieving ≥50% reduction in Pittsburgh Sleep Quality Index (PSQI) total score
Tijdsspanne: Week 4, Week 8
|
The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported instrument designed to assess sleep quality over the preceding month, with total scores ranging from 0 to 21, where higher scores denote poorer sleep quality.
|
Week 4, Week 8
|
|
Sleep efficiency measured by actigraphy
Tijdsspanne: Baseline, Week 4
|
Baseline, Week 4
|
|
|
Total sleep time measured by actigraphy
Tijdsspanne: Baseline, Week 4
|
Baseline, Week 4
|
|
|
Incidence of adverse events
Tijdsspanne: From baseline to Week 8
|
From baseline to Week 8
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Resting-state electroencephalography-derived microstate parameters
Tijdsspanne: Baseline, Week 4
|
Resting-state electroencephalography-derived microstate parameters, including mean duration, occurrence rate, time coverage, and transition probability, will be assessed at baseline and week 4. Mean duration refers to the average time for which a microstate class remains stable; occurrence rate refers to the number of occurrences per second; time coverage refers to the percentage of total recording time occupied by a microstate class; and transition probability refers to the probability of transition from one microstate class to another.
|
Baseline, Week 4
|
|
Untargeted plasma metabolomic features
Tijdsspanne: Baseline, Week 4
|
Fasting plasma samples will be collected at baseline and week 4 and analyzed using an untargeted metabolomics approach based on ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS).
Detected metabolomic features will be characterized by mass-to-charge ratio, retention time, relative ion intensity, and tandem mass spectrometry spectra.
|
Baseline, Week 4
|
|
Credibility/Expectancy Questionnaire scores
Tijdsspanne: Baseline
|
Treatment credibility and expectancy will be assessed before treatment using the Credibility/Expectancy Questionnaire.
The credibility subscale consists of three items rated on a 1-9 scale, with a total score ranging from 3 to 27; higher scores indicate greater perceived treatment credibility.
The expectancy subscale consists of three items assessing expected improvement and perceived treatment benefit.
Two items are rated from 0% to 100%, and one item rated on a 1-9 scale will be transformed to a 0-100 scale; the three items will be averaged to generate a score ranging from 0 to 100, with higher scores indicating greater treatment expectancy.
|
Baseline
|
|
Bang blinding index
Tijdsspanne: Week 4
|
At week 4, before unblinding, participants will complete a structured blinding assessment question asking them to guess their treatment allocation as real electroacupuncture, sham electroacupuncture, or "uncertain."
Blinding success will be quantified using the Bang blinding index and its 95% confidence interval.
The Bang blinding index ranges from -1 to 1, with values close to 0 indicating successful blinding.
Values between -0.2 and 0.2 will be interpreted as indicating adequate blinding.
|
Week 4
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 mei 2026
Primaire voltooiing (Geschat)
1 februari 2027
Studie voltooiing (Geschat)
1 maart 2027
Studieregistratiedata
Eerst ingediend
28 april 2026
Eerst ingediend dat voldeed aan de QC-criteria
4 mei 2026
Eerst geplaatst (Werkelijk)
8 mei 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
8 mei 2026
Laatste update ingediend die voldeed aan QC-criteria
4 mei 2026
Laatst geverifieerd
1 mei 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pijn
- Neurologische manifestaties
- Botziekten
- Musculoskeletale aandoeningen
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Pathologische aandoeningen, anatomisch
- Neuromusculaire aandoeningen
- Ziekten van het perifere zenuwstelsel
- Spinale ziekten
- Slaap-waakstoornissen
- Hernia
- Slaapstoornissen, intrinsiek
- Dyssomnieën
- Neuralgie
- Mononeuropathieën
- Ischias neuropathie
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Verplaatsing van de tussenwervelschijf
- Slaapinitiatie en -onderhoudsstoornissen
- Ischias
- Therapeutica
- Complementaire therapieën
- Modaliteiten fysiotherapie
- Revalidatie
- Anesthesie en analgesie
- Elektrische stimulatietherapie
- Gecombineerde modaliteitstherapie
- Anesthesie
- Analgetie
- Acupunctuurtherapie
- Transcutane elektrische zenuwstimulatie
- Elektroacupunctuur
Andere studie-ID-nummers
- 2026-084
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .